A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

NCT00001498 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Breast Cancer
Breast Neoplasms

Interventions

DRUG: methotrexate
DRUG: leucovorin
DRUG: 5-fluorouracil
DRUG: cyclophosphamide
PROCEDURE: peripheral blood progenitor cell
DRUG: paclitaxel
DRUG: doxorubicin

Sponsor

National Cancer Institute (NCI)